...
Kadmon Holdings
Performance
Dividends
18/36
Growth Score
6/36
Dividend Score
Valuation
PE Ratio
-13.71
PS Ratio
102
3
RSI
0
0
PEG Ratio
0
0
PRG Ratio
0
PDG Ratio
0
Growth
3265%363%-2%0%
-13%-77%6%0%
2023
2024
2025*
2026*
3
Revenue
Revenue
*Analyst estimated growth
Fundamentals
0
Rule of 40
0%
3
Gross Margin
93.83%
3
Current Ratio
6.32
Return on Assets
-39.51%
Return on Equity
-216.47%
Return on inv. Capital
-45.06%
Institutional Holder
71.460.625069.733.779
11334
Shares
Holders
Financials
Yealy
Quarterly
Revenue 2020 8.29M
-62%-27%-52%-88%264%62%
2014
2015
2016
2017
2018
2019
2020
6
Net Income 2020 -108.91M
-128%-41%61%31%-13%-77%
2014
2015
2016
2017
2018
2019
2020
6
Gross Profit 2020 6.29M
-64%-25%-58%-92%433%65%
2014
2015
2016
2017
2018
2019
2020
6
About
Sector/Industry
Healthcare
Biotechnology
IPO Date
27.07.2016
MaketCap
1.65B
Country
US
CEO
Dr. Harlan Waksal
Description
Kadmon Holdings, Inc., a biopharmaceutical company, discovers, develops, and commercializes small molecules and biologics primarily for the treatment of inflammatory and fibrotic diseases. Its lead product candidates include KD025, an orally administered selective inhibitor of the rho-associated coiled-coil kinase 2, which is in Phase II clinical trial for the treatment of chronic graft-versus-host and fibrotic diseases; KD045, an oral inhibitor of ROCK for the treatment of fibrotic diseases; and KD033, an anti-PD-L1/IL-15 fusion protein for the treatment of cancer. The company also engages in developing Tesevatinib to treat autosomal dominant polycystic kidney disease; ribavirin, a nucleoside Inhibitor to treat hepatitis; and CLOVIQUE, a trientine hydrochloride capsules for the treatment of Wilson's disease. Kadmon Holdings, Inc. has strategic collaborations and license agreements with Nano Terra, Inc. and Dyax Corp. The company was founded in 2010 and is headquartered in New York, New York.
Updated 15.03.2022